SCM
CAMP icon

Stonepine Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History

Stonepine Capital Management’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.13M Buy
1,389,622
+1,160,728
+507% +$5.51M 2.45% 8
2025
Q4 		$1.4M Buy
+228,894
New +$974K 1.02% 29

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Stonepine Capital Management's CAMP Position: Q1 2026 in Review

Stonepine Capital Management increased its CAMP4 Therapeutics (CAMP) stake by 507% in Q1 2026, buying an estimated $5.51M and bringing the position to 1,389,622 shares worth $6.13M. The position accounts for 2.45% of the portfolio, ranked #8.

Stonepine Capital Management first reported a position in CAMP in Q4 2025 and has held it in 2 quarters since. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Stonepine Capital Management held 1,389,622 shares of CAMP4 Therapeutics worth $6.13M as of Q1 2026.
  • Stonepine Capital Management bought 1,160,728 CAMP4 Therapeutics shares in Q1 2026, an estimated $5.51M.
  • CAMP4 Therapeutics made up 2.45% of Stonepine Capital Management's portfolio in Q1 2026, its #8 holding.
  • Stonepine Capital Management first reported a position in CAMP4 Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.